Comparing Immediate Stem Cell Transplant With Bridging Therapy in Higher-Risk MDS
Compares immediate stem cell transplant with bridging therapy first in adults with higher-risk myelodysplastic syndrome.
Plain-language title generated from the registry record
Registry title: Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Key facts
- Where
- Beijin, Chengdu, Jinan, Shijia Zhuang, and Zhengzhou, ChinaSee the 5 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with higher-risk myelodysplastic syndrome who can have a donor stem cell transplant. It compares transplant right away with transplant after bridging treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Higher-risk myelodysplastic syndrome: IPSS-R score of 3.5 or more, or IPSS-M risk of intermediate-high, high or very high
- Earlier treatment
- People who have already had a donor stem cell transplant cannot join
Main reasons for not taking part
- Heart pumping (left ventricular ejection fraction) below 50%
- Need for extra oxygen
- Serious liver problems (bilirubin above 1.5x normal, or AST/ALT above 5x normal)
- Kidney function (eGFR) below 50 mL/min
- Earlier donor stem cell transplant
Read by machine on 12 November 2026.
Where in China
- Peking University People's HospitalBeijin, ChinaContact: Hao JiangTaking people
- People's Liberation Army The General Hospital of Western Theater CommandChengdu, ChinaContact: hai yiTaking people
- The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation ArmyJinan, ChinaContact: FANG ZHOUTaking people
- The Second Hospital of Hebei Medical UniversityShijia Zhuang, ChinaContact: Fuxu WangTaking people
- Zhengzhou University - First Affiliated HospitalZhengzhou, ChinaContact: weijie caoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT06918834
- Record updated
- 12 September 2025
- Original description
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).Read full original descriptionShow less
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients: A Multicenter, Randomized Controlled, Open-Label, Phase 2 Clinical Trial
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Inclusion: Age ≥18 years; High relapse risk MDS, defined by:; IPSS-R score ≥3.5; IPSS-M stratification as intermediate-high, high, or very high risk; Eligible for allogeneic HSCT (including matched or mismatched related/unrelated donor transplantations); Karnofsky Performance Status (KPS) ≥60; Signed informed consent.
Exclusion: History of prior allogeneic HSCT; Any condition deemed unsuitable by the investigator; Severe organ dysfunction:; Left ventricular ejection fraction <50%; Oxygen supplementation requirement; Serum bilirubin >1.5x upper limit of normal (unless due to Gilbert syndrome) or AST/ALT >5x upper limit of normal; Estimated glomerular filtration rate (eGFR) <50 mL/min.